Acute changes in cardiac function by direct acting antiviral therapy for hepatitis C−infected patients with thalassemia. Issue 3 (9th October 2018)

• Record Type: Journal Article
• Authors: Khosravi, Arezoo; Karimi‐Sari, Hamidreza; Abedi‐Andani, Mahdi; Behnava, Bita; Namvar, Ali; Anvar, Ali; Alavian, Seyed Moayed
• Is Part Of: Journal of medical virology. Volume 91:Issue 3(2019)
• Page Start: 419
• Page End: 427
• Publication Date: 2018-10-09
• Subjects: cardiac function -- echocardiography -- hepatitis C -- ledipasvir -- sofosbuvir -- thalassemia; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.25314
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract : Background: Patients with thalassemia may also have cardiac abnormalities due to congenital problems, anemia, and increased burden of iron in their myocardium. This study was designed to evaluate the effects of direct acting antiviral (DAA) therapy on the cardiac function of hepatitis C virus (HCV)–infected patients with thalassemia. Method: HCV−infected thalassemia patients were enrolled to this prospective evaluation. Daily tablets of 90 mg Ledipasvir (or 60 mg Daclatasvir) plus 400 mg Sofosbuvir (±ribavirin) were prescribed for the patients according to the Iran Hepatitis Network's guidelines. An echocardiography fellow collected the echocardiography findings before and after the treatment of all the patients. The patients were followed up for any cardiac events within 12 weeks after finishing the treatment. Results: Thirty‐two patients with the mean age of 24.2 ± 6.4 years were evaluated. All patients showed a sustained virological response at the 12th week after finishing the treatment. The patients' left ventricular end systolic diameter (3.0 vs 3.24; P = 0.003) and volume (33.8 vs 43.6; P = 0.001), global longitudinal strain of the left ventricle (−22.0 vs −20.6, P = 0.046), and average (−21.4 vs −20.3; P = 0.048), and the right ventricle size (3.12 vs 3.31; P = 0.012) were significantly increased after finishing the treatment. Changes in the abovementioned parameters were not correlated with the patients' myocardium iron load. There were no significant differences in other echocardiographic parameters ( P > 0.05) before and after the treatment. Conclusion: Sofosbuvir‐based regimens for HCV treatment were safe for our HCV−infected patients with thalassemia. Our patients' ejection fraction remained unchanged. Hence, more specialized echocardiographic evaluations were recommended for those with a history of cardiac abnormalities, cardiac iron overload, and in case of any cardiac adverse event during DAA therapy in patients with thalassemia.